RERGL Inhibitors
Chemical inhibitors of RERGL function by modulating various signaling pathways that RERGL is known to be a part of, particularly the PI3K/Akt pathway and its associated networks. Phloretin, LY294002, and Wortmannin are compounds that directly inhibit the PI3K/Akt signaling pathway. Phloretin accomplishes this by blocking the pathway, thereby reducing the activation of RERGL, which is dependent on the signaling provided by PI3K/Akt. LY294002 and Wortmannin also target this pathway; LY294002 is a potent inhibitor of PI3K itself, leading to a decrease in RERGL activity due to the lowered PI3K/Akt pathway activity. Wortmannin operates in a similar fashion, preventing the phosphorylation and activation of Akt, which is an essential step for RERGL activity within the pathway. Triciribine and MK-2206 specifically target Akt, and by doing so, they reduce the overall signaling through the PI3K/Akt pathway, which in turn decreases RERGL activity.
In addition to targeting the PI3K/Akt pathway, some inhibitors affect RERGL activity by acting on pathways that interact with PI3K/Akt. Rapamycin inhibits the mTOR pathway, which has regulatory interactions with the PI3K/Akt pathway, thus affecting RERGL activity indirectly. PD98059 and U0126 are both inhibitors of MEK, which is part of the MAPK/ERK pathway, a pathway that can cross-talk with the PI3K/Akt pathway. By inhibiting MEK, these compounds can lead to a decrease in RERGL activity, considering the interconnected nature of these signaling routes. SB203580 takes a different approach by inhibiting p38 MAPK, which can influence the PI3K/Akt pathway and subsequently RERGL activity. SP600125 inhibits JNK, a kinase that is part of signal transduction pathways that interact with the PI3K/Akt pathway. Finally, LY3214996 and PF-4708671 inhibit ERK1/2 and p70S6 kinase (S6K1), respectively, both of which are related to the regulatory pathways that affect RERGL activity, further illustrating the complex network of interactions that govern the function of RERGL.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
Phloretin inhibits the PI3K/Akt signaling pathway, which is a pathway RERGL is known to be part of. By inhibiting this pathway, Phloretin can decrease the activity of RERGL, as PI3K/Akt is crucial for its activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which directly reduces PI3K/Akt pathway activity. Reduced PI3K activity leads to decreased RERGL function, as RERGL activity is dependent on this signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that prevents the phosphorylation and activation of Akt, thereby inhibiting the PI3K/Akt pathway and subsequently decreasing RERGL activity since RERGL operates within this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which interacts with the PI3K/Akt pathway. By inhibiting mTOR, Rapamycin can indirectly lead to reduced RERGL activity as the mTOR pathway has regulatory interactions with the pathways that RERGL is part of. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway. Since RERGL is associated with the PI3K/Akt pathway, which can cross-talk with the MAPK/ERK pathway, inhibition of MEK can lead to a reduction in RERGL activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also targets MEK in the MAPK/ERK pathway. Similar to PD98059, it indirectly decreases RERGL activity by inhibiting the MAPK/ERK pathway, which has regulatory interactions with the PI3K/Akt pathway that RERGL is part of. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK, another kinase that can influence the PI3K/Akt pathway. By inhibiting p38 MAPK, SB203580 can lead to decreased RERGL activity, as RERGL relies on the proper functioning of the PI3K/Akt pathway for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is implicated in various signal transduction pathways that can interact with the PI3K/Akt pathway. Inhibition of JNK may lead to reduced RERGL activity, as RERGL is dependent on this interconnected signaling network. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits Akt, a critical component of the PI3K/Akt pathway. By inhibiting Akt, Triciribine can decrease RERGL activity, as RERGL's function is known to be coupled to this pathway. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 is a selective ERK1/2 inhibitor. By inhibiting ERK1/2, it decreases the activity of the MAPK/ERK pathway, which interacts with the PI3K/Akt pathway. Reduced signaling through MAPK/ERK can lead to less RERGL activity. | ||||||